IQVIA Holdings Inc. (NYSE:IQV) Stake Cut by Callan Family Office LLC

Callan Family Office LLC reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 22.0% in the 1st quarter, Holdings Channel reports. The fund owned 1,408 shares of the medical research company’s stock after selling 397 shares during the period. Callan Family Office LLC’s holdings in IQVIA were worth $248,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of IQV. American National Bank & Trust purchased a new stake in IQVIA in the 1st quarter worth about $26,000. Golden State Wealth Management LLC lifted its stake in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC purchased a new stake in IQVIA in the 1st quarter worth about $33,000. ST Germain D J Co. Inc. lifted its stake in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares in the last quarter. Finally, GKV Capital Management Co. Inc. purchased a new stake in IQVIA in the 4th quarter worth about $39,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Performance

NYSE:IQV opened at $189.50 on Friday. The firm’s 50-day moving average is $169.61 and its 200-day moving average is $168.92. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $32.21 billion, a price-to-earnings ratio of 27.42, a PEG ratio of 2.09 and a beta of 1.30.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter in the previous year, the firm posted $2.64 EPS. The business’s revenue was up 5.3% compared to the same quarter last year. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Redburn Partners set a $188.00 price target on IQVIA in a research note on Friday, May 23rd. Hsbc Global Res lowered shares of IQVIA from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 25th. Citigroup reissued a “neutral” rating on shares of IQVIA in a research report on Thursday, May 22nd. HSBC downgraded shares of IQVIA from a “buy” rating to a “hold” rating and cut their price target for the company from $260.00 to $160.00 in a report on Friday, April 25th. Finally, Barclays upped their price objective on shares of IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $228.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.